{"type":"rich","version":"1.0","title":"Pharmaceutical Executive Daily: FDA Approves Simtriyo ","description":"In today's Pharmaceutical Executive Daily, FDA approves Otsuka's Simtriyo as the first NDSRI treatment for ADHD, argenx agrees to acquire Forte Biosciences for approximately $2.2 billion, and an AbbVie neuroscience researcher discusses the shift from symptom management to disease modification in Parkinson's research.","author_name":"Pharmaceutical Executive","author_url":"https://audioboom.com/channels/5120049-pharmaceutical-executive","provider_name":"Audioboom","provider_url":"https://audioboom.com","width":480,"height":95,"thumbnail_url":"https://audioboom.com/i/43762129/600x600/c","thumbnail_width":600,"thumbnail_height":600,"html":"<iframe width=\"100%\" height=\"95\" src=\"https://embeds.audioboom.com/posts/8932941/embed?v=202301\" style=\"background-color: transparent; display: block; padding: 0; width: 100%\" frameborder=\"0\" allowtransparency=\"allowtransparency\" scrolling=\"no\" title=\"Audioboom player\" allow=\"autoplay\" sandbox=\"allow-downloads allow-forms allow-popups allow-same-origin allow-scripts allow-storage-access-by-user-activation allow-top-navigation-by-user-activation\"></iframe>"}